Stemline Therapeutics Inc (STML)

6.62
0.33 4.70
NASDAQ : Health Care
Prev Close 6.95
Open 6.95
Day Low/High 6.55 / 6.95
52 Wk Low/High 3.88 / 12.44
Volume 162.76K
Avg Volume 339.60K
Exchange NASDAQ
Shares Outstanding 23.66M
Market Cap 160.88M
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Stemline Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Stemline Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

Newman Ferrara LLP Announces Corporate Governance Investigation Of Stemline Therapeutics Inc.

Newman Ferrara LLP Announces Corporate Governance Investigation Of Stemline Therapeutics Inc.

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline Therapeutics Inc.

STML LOSS NOTICE: Rosen Law Firm Reminds Stemline Therapeutics, Inc. Investors Of Important Deadline In First Class Action Filed By Firm - STML

STML LOSS NOTICE: Rosen Law Firm Reminds Stemline Therapeutics, Inc. Investors Of Important Deadline In First Class Action Filed By Firm - STML

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Stemline Therapeutics, Inc.

Short Interest In Stemline Therapeutics Drops 44.6%

Short Interest In Stemline Therapeutics Drops 44.6%

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 599,096 share decrease in total short interest for Stemline Therapeutics Inc , to 744,915, a decrease of 44.58% since 01/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Explode Up Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Kirby McInerney LLP Advises Stemline Therapeutics, Inc. Investors Of Potential Claims

Kirby McInerney LLP Advises Stemline Therapeutics, Inc. Investors Of Potential Claims

The law firm of Kirby McInerney LLP announced today that a class action lawsuit has been filed in the United States District Court for the Southern District of New York against Stemline Therapeutics, Inc.

INVESTOR ALERT: Law Offices Of Howard G. Smith Commences Investigation On Behalf Of Stemline Therapeutics, Inc. Investors

INVESTOR ALERT: Law Offices Of Howard G. Smith Commences Investigation On Behalf Of Stemline Therapeutics, Inc. Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Stemline Therapeutics, Inc.

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Stemline Therapeutics, Inc. - STML

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Stemline Therapeutics, Inc. - STML

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of Stemline Therapeutics, Inc.

INVESTOR ALERT: Abraham, Fruchter & Twersky LLP Announces Investigation Of Securities Claims Against Stemline Therapeutics, Inc. - STML

INVESTOR ALERT: Abraham, Fruchter & Twersky LLP Announces Investigation Of Securities Claims Against Stemline Therapeutics, Inc. - STML

Abraham, Fruchter & Twersky, LLP announces that it is investigating potential claims on behalf of investors who purchased shares of Stemline Therapeutics, Inc.

Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial; Company Raises Money

Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial; Company Raises Money

Stemline's SL-401 has demonstrated robust overall tumor response rates in its clinical trial, but the drug is also now tied to three patient deaths from capillary leak syndrome.

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces An Investigation Of Stemline Therapeutics, Inc. And Encourages Investors To Contact The Firm

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces An Investigation Of Stemline Therapeutics, Inc. And Encourages Investors To Contact The Firm

Khang & Khang LLP (the "Firm") announces that it is investigating claims against Stemline Therapeutics, Inc.

New York Metro Superlawyer, Lynda J. Grant, Investigates Potential Fraud Claims Against Stemline Therapeutics, Inc. (

New York Metro Superlawyer, Lynda J. Grant, Investigates Potential Fraud Claims Against Stemline Therapeutics, Inc. ("STML: NASDAQ")

Lynda J. Grant, an attorney with over 30 years of experience representing wronged shareholders and consumers and a New York Metro Superlawyer, announces that TheGrantLawFirm, PLLC is investigating potential claims that...